INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,453 | -15.0% | 27,900 | +3.3% | 0.01% | -14.3% |
| Q2 2023 | $1,709 | -49.1% | 27,000 | -56.5% | 0.01% | +40.0% |
| Q1 2023 | $3,360 | +194.0% | 62,100 | +187.5% | 0.01% | 0.0% |
| Q4 2022 | $1,143 | -99.9% | 21,600 | -30.1% | 0.01% | -28.6% |
| Q3 2022 | $1,437,000 | -18.5% | 30,900 | 0.0% | 0.01% | -12.5% |
| Q2 2022 | $1,763,000 | +123.4% | 30,900 | +139.5% | 0.01% | +166.7% |
| Q1 2022 | $789,000 | +81.8% | 12,900 | +55.4% | 0.00% | +50.0% |
| Q4 2021 | $434,000 | +57.8% | 8,300 | +12.2% | 0.00% | +100.0% |
| Q3 2021 | $275,000 | -8.9% | 7,400 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $302,000 | +308.1% | 7,400 | +155.2% | 0.00% | – |
| Q3 2020 | $74,000 | -40.8% | 2,900 | -40.8% | 0.00% | -100.0% |
| Q2 2020 | $125,000 | +95.3% | 4,900 | +3.4% | 0.00% | – |
| Q3 2014 | $64,000 | – | 4,740 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |